Your Health, We Care
Release date: 2026-02-04 17:23:50 Article From: Lucius Laos Recommended: 8
Patients should take pirfenidone with meals at a fixed time every day to reduce the incidence of adverse reactions such as nausea and dizziness. For patients taking strong or moderate CYP1A2 inhibitors, the dosage may need to be adjusted due to drug-drug interactions.
The use of a daily dose exceeding 2403 milligrams is not recommended for any patients.
Strategies to help patients establish a daily pirfenidone medication routine
Take pirfenidone with meals at a fixed time daily to help patients maintain consistent medication adherence.
Patients can set timers or alarms to remind themselves of the next dose.
The 267-milligram strength tablets are specifically designed for step-up titration to the full dosage.
For maintenance treatment, patients should take the 801-milligram strength tablets: 1 tablet per time, 3 times a day.
Once patients tolerate the full dosage of 3 tablets of the 267-milligram strength per administration, 3 times a day, well, they may switch to the maintenance regimen of 1 tablet of the 801-milligram strength per time, 3 times a day, which reduces the number of tablets taken daily.
Take pirfenidone with breakfast, lunch, and dinner to help patients form a meal-associated medication habit and alleviate gastrointestinal adverse reactions.
Patients should start pirfenidone treatment with the 267-milligram strength tablets.
Liver function tests should be performed regularly before starting pirfenidone treatment and during the treatment period.
Titrate the patient’s dosage to the recommended daily dose gradually within 14 days: 3 tablets of the 267-milligram strength per administration, 3 times a day, taken with meals.
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended：832025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended：3752024-09-07
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended：742025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended：952025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended：902025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended：1052025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended：1032025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended：1002025-27-11
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp:
